RT Journal Article
SR Electronic
T1 Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00060-2022
DO 10.1183/23120541.00060-2022
VO 8
IS 4
A1 Kseniia Suska
A1 Francesco Amati
A1 Giovanni Sotgiu
A1 Andrea Gramegna
A1 Marco Mantero
A1 Margherita Ori
A1 Maurizio Ferrarese
A1 Luigi Ruffo Codecasa
A1 Anna Stainer
A1 Francesco Blasi
A1 Stefano Aliberti
YR 2022
UL http://openres.ersjournals.com/content/8/4/00060-2022.abstract
AB Background Although interest in nontuberculous mycobacteria (NTM) infection has increased in the last decades, published data vary according to different geographical areas, diagnostic facilities and quality of study design. This study aims at assessing both prevalence and incidence of NTM infection and NTM pulmonary disease (NTM-PD) among adults with bronchiectasis, to describe patients’ characteristics, therapeutic options and clinical outcomes.Methods Bronchiectasis adults who had been tested for NTM were enrolled at the Bronchiectasis Program of the Policlinico Hospital in Milan, Italy, from 2016 to 2018.Results Among the 373 patients enrolled, 26.1% had at least one respiratory sample positive for NTM and 12.6% reached a diagnosis of NTM-PD. Incidence rates for NTM infection and NTM-PD were 13 (95% CI 10–16) and 4 (95% CI 2–6) per 100 person-years, respectively. The most prevalent NTM species causing NTM-PD were M. intracellulare (38.3%), M. avium (34.0%), M. abscessus (8.5%) and M. kansasii (8.5%). Once treatment for NTM-PD was initiated, a favourable outcome was documented in 52.2% of the patients, while a negative outcome was recorded in 32.6%, including recurrence (17.4%), treatment failure (10.9%), re-infection (2.2%) and relapse (2.2%). Treatment halted was experienced in 11 (23.9%) patients.Conclusions NTM infection is frequent in bronchiectasis patients and the presence of NTM-PD is relevant. The low success rate of NTM-PD treatment in bronchiectasis patients requires a call to action to identify new treatment modalities and new drugs to improve patients’ outcomes.The low success rate of NTM pulmonary disease treatment in bronchiectasis patients necessitates a call to action to find novel treatment modalities and new drugs to improve outcomes https://bit.ly/3aNcBVd